614 results on '"Lenting, Peter J."'
Search Results
2. Angiopoietin-2 binds to multiple interactive sites within von Willebrand factor
3. Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy
4. Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models
5. Antithrombin lowering in hemophilia: a closer look at fitusiran
6. A reactive center loop–based prediction platform to enhance the design of therapeutic SERPINs
7. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD
8. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab
9. Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S
10. Osteoprotegerin modulates platelet adhesion to von Willebrand factor during release from endothelial cells
11. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis
12. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID‐19
13. Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications
14. Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation
15. Laboratory monitoring of hemophilia A treatments: new challenges
16. Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc
17. A single‐domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor
18. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia
19. von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week
20. Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor
21. IdeS, a new option to optimize the management of patients with hemophilia A on emicizumab
22. Real-Time Monitoring of von Willebrand Factor in the Catheterization Laboratory: The Seatbelt of Mini-Invasive Transcatheter Aortic Valve Replacement?
23. Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support
24. Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
25. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
26. Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19
27. Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions
28. Author Correction: Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
29. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A
30. VON WILLEBRAND FACTOR: FROM FIGURANT TO MAIN CHARACTER IN THE SCENE OF INFLAMMATION
31. Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X
32. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends
33. A nanobody against the von Willebrand factor A3-domain detects ADAMTS13-induced proteolysis in congenital & acquired VWD
34. A FVIII-Mimetic Bispecific Antibody with an Embedded Self-Regulation Mechanism Reduces the Risk of Prothrombotic Events for the Treatment of Haemophilia a
35. P.31 Von Willebrand Factor Induces Vascular Smooth Muscle Cell Proliferation and Migration Through Low Density Lipoprotein-Related Receptor Protein 4 and αvβ3 Integrin
36. Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort
37. von Willebrand Factor for Aortic Valve Intervention: From Bench to Real-Time Bedside Assessment
38. Abstract 19793: Pulsatility Modulates the Acquired Von Willebrand Factor Defect Related to Mechanical Circulatory Support Devices
39. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B–associated thrombocytopenia
40. Identification of von Willebrand factor D4 domain mutations in patients of Afro‐Caribbean descent: In vitro characterization
41. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
42. Mutations in the A3 domain of Von Willebrand factor inducing combined qualitative and quantitative defects in the protein
43. A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation—Brief Report
44. A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor
45. Of von Willebrand factor and platelets
46. TaSER: Combining forces to stop the clot
47. Macrophage LRP1 contributes to the clearance of von Willebrand factor
48. A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated von Willebrand disease type 2B patient
49. Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA
50. Factor VIII Accelerates Proteolytic Cleavage of von Willebrand Factor by ADAMTS13
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.